@1957 About time!
Posts tagged Value Pickr
Sanghvi Movers (28-06-2024)
Interview with ET NOW
-
FY 25 Rev to be between 950-1000 cr. Current Order Book 600-650 cr (all executable in FY 25).
-
60:40 split between Rental and EPC. Rental margins 60-62%, EPC to be 10-12%.
-
10 GW enquiry pipeline. Capacity Utilisation > 80% (theoretically 100%).
Sanghvi Movers: Revenue, Order Pipeline & Margin Guidance | Bidding On EPC Projects | Rishi Sanghvi
Ugro Capital – Opportunity To Invest in a Fintech-like Company Below Book Value (28-06-2024)
It will improve as they build the infra first and will scale now. look at their ROE and ROA targets for next year.
Smallcap momentum portfolio (28-06-2024)
@Mudit.Kushalvardhan I still believe my previous message is appropriate and one should not mix momentum with any other strategy. By doing that, we are diluting the returns only.
In all cases, you will find that price action precedes news. If we look for fundamentals or do stage analysis, you might find that most stocks will not qualify.
In fact, what are we trying to do in a momentum pf. We are trying to get in and out of a stock that has momentum. We want to catch the price action. Why do we want to question why it has gone up? If we believe that market knows better than us, just follow the price action.
You might still want to have another pf that is based on fundamentals or technicals, but it does not make sense to couple it with momentum.
Concord Control Systems – An SME railway stock (28-06-2024)
Well, as you said, not much information about this is available. Turnover is also small. I would like them to prove themselves consistently for sometime (multi fold growth, not linear growth which is there in their balance sheet right now).
We already have other good stocks in railway to go for (like texrail).
I may be wrong as well!
StageInvesting +Elliot Waves (28-06-2024)
Wockhardt CMP 686
Going as per the projection given in Dec 2023
Newsflow is also positive
ps://www.financialexpress.com/business/healthcare-wockhardt-claims-breakthrough-in-cancer-treatment-httwith-experimental-drug-zaynich-us-body-awards-highest-susceptibility-to-the-antibiotic-3537791/
Atma Nirbhar Bharat – Stock opportunities (28-06-2024)
Excellent analysis. Thank you for sharing this. If you can enlighten us further on
- As you said Mazgaon could be the next OFS. And price might fall
- But Mazgaon has the highest orders right now. Plus it has the lowest PE.
Thus I think, it will not fall that much (yes it will fall, but not to the price of what we can buy Mazgaon today or this week.
So this is right time to enter Mazgaon at today’s price and current PE.
This is my thinking. I might be wrong.
Indian Defense Sector (28-06-2024)
Hi, can you share list of front line, defense shipping, ancillaries companies? as you have highlighted in your comment.
Thank you very much.
Alkem Laboratories Ltd: Indian pharmaceutical company growing consistently (28-06-2024)
Alkem Labs -
Key highlights from FY 24 -
Continues to rank no 1 in Anti Infectives, No 2 in Vit/Min space in India
India business contributes to 68 pc of sales, grew by 5.4 pc
US business contributes to 21 pc of sales, grew by 10 pc
Rest comes from RoW mkts ( LATAM, Australia, EU ), grew strongly at 33 pc
Cash on Books @ 3550 cr
Anti-Infectives mkts were sluggish throughout FY 24, which affected company’s India performance. However, the company continued to do well in Anti-Diabetic, GI, Vit/Minerals and Derma therapies
Lesser pricing pressures in US and descent volume growth in US + RoW business helped improve overall gross margins. Company believes that the worst of pricing pressures in the US business should now be behind
Company’s domestic biosimilar business ( under its Subsidiary - ENZENE ), with 7 brands continues to ramp up well
Aim to grow revenues by 10 pc in FY 25 with stable gross and EBITDA margins ( with an upward bias )
Capex lined up for FY 25 @ around 600 cr
Expecting the anti-invectives mkt to pick up in FY 25 ( as FY 24 was exceptionally weak for this segment ). If this happens, company may outperform its guidance
30 pc of company’s India products are under NLEM
Company has the largest trade generics business in the country. At the same time, the branded generics business continues to do well. Company believes, both can do well simultaneously
As the company’s chronic business ramps up in India, Margins should improve further over the medium term
Launched 3 new products in US in FY 24. Going to launch 6 new products in US in FY 25
Expect to maintain 4.5 of sales as R&D expenses going fwd
Setting up a Bio-Similars plant in US under its Bio-Similars subsidiary - ENZENE. It’s mainly going to engage in contract manufacturing operations. Expect it to contribute meaningfully from FY 27. Capex required here should be around 400 cr
MR productivity for the company is 4.5 lakh / month. On the chronic business side, its about 3.5 lakh / month - clearly there is a lot of headroom to improve the productivity here
Company’s share of Chronic business is low at present @ 18 pc. There is a huge scope of improvement here. Expect it to cross 20 pc in next 2-3 yrs
Total MR strength for the company is around 12000
Trade generics contribute to around 20 pc of company’s India business
Company is working on another 5 biosimilars to be launched in India under its subsidiary - ENZENE
Cash on books - in all likelihood to be used to inorganic acquisitions - specially in the Chronic segment. Actively looking out for the same
Company is setting up a new business division - to manufacture medical devices. Will update investors as the business goes commercial. Focus here will be on the domestic Mkts to begin with
Disc: holding, Biased, Not SEBI registered
Ranvir’s Portfolio (28-06-2024)
Alkem Labs -
Key highlights from FY 24 -
Continues to rank no 1 in Anti Infectives, No 2 in Vit/Min space in India
India business contributes to 68 pc of sales, grew by 5.4 pc
US business contributes to 21 pc of sales, grew by 10 pc
Rest comes from RoW mkts ( LATAM, Australia, EU ), grew strongly at 33 pc
Cash on Books @ 3550 cr
Anti-Infectives mkts were sluggish throughout FY 24, which affected company’s India performance. However, the company continued to do well in Anti-Diabetic, GI, Vit/Minerals and Derma therapies
Lesser pricing pressures in US and descent volume growth in US + RoW business helped improve overall gross margins. Company believes that the worst of pricing pressures in the US business should now be behind
Company’s domestic biosimilar business ( under its Subsidiary - ENZENE ), with 7 brands continues to ramp up well
Aim to grow revenues by 10 pc in FY 25 with stable gross and EBITDA margins ( with an upward bias )
Capex lined up for FY 25 @ around 600 cr
Expecting the anti-invectives mkt to pick up in FY 25 ( as FY 24 was exceptionally weak for this segment ). If this happens, company may outperform its guidance
30 pc of company’s India products are under NLEM
Company has the largest trade generics business in the country. At the same time, the branded generics business continues to do well. Company believes, both can do well simultaneously
As the company’s chronic business ramps up in India, Margins should improve further over the medium term
Launched 3 new products in US in FY 24. Going to launch 6 new products in US in FY 25
Expect to maintain 4.5 of sales as R&D expenses going fwd
Setting up a Bio-Similars plant in US under its Bio-Similars subsidiary - ENZENE. It’s mainly going to engage in contract manufacturing operations. Expect it to contribute meaningfully from FY 27. Capex required here should be around 400 cr
MR productivity for the company is 4.5 lakh / month. On the chronic business side, its about 3.5 lakh / month - clearly there is a lot of headroom to improve the productivity here
Company’s share of Chronic business is low at present @ 18 pc. There is a huge scope of improvement here. Expect it to cross 20 pc in next 2-3 yrs
Total MR strength for the company is around 12000
Trade generics contribute to around 20 pc of company’s India business
Company is working on another 5 biosimilars to be launched in India under its subsidiary - ENZENE
Cash on books - in all likelihood to be used to inorganic acquisitions - specially in the Chronic segment. Actively looking out for the same
Company is setting up a new business division - to manufacture medical devices. Will update investors as the business goes commercial. Focus here will be on the domestic Mkts to begin with
Disc: holding, Biased, Not SEBI registered